U.S. Markets open in 8 hrs 41 mins

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.86-1.24 (-4.75%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close26.10
Open25.74
Bid0.00 x 1100
Ask0.00 x 800
Day's Range24.38 - 26.10
52 Week Range8.51 - 43.56
Volume705,439
Avg. Volume1,810,340
Market Cap1.963B
Beta (5Y Monthly)1.64
PE Ratio (TTM)N/A
EPS (TTM)-3.08
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est54.33
  • Is Intra-Cellular Therapies' (NASDAQ:ITCI) 195% Share Price Increase Well Justified?
    Simply Wall St.

    Is Intra-Cellular Therapies' (NASDAQ:ITCI) 195% Share Price Increase Well Justified?

    Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares...

  • 2 Top Biotech Stocks to Buy in October
    Motley Fool

    2 Top Biotech Stocks to Buy in October

    With traders everywhere scrambling to pick up the best coronavirus vaccine stocks amid a volatile and unpredictable market, it's no surprise that long-term-minded biotech investors are looking for companies that will provide lasting returns. In my view, the best biotech companies have a narrow strategic focus that they hammer on from multiple angles with cohesive product development, thereby capturing a larger share of their target markets in comparison to the competition. Furthermore, both have exciting projects in late-stage clinical trials, so they're timely to purchase.

  • New Ventures Funds Rebrands as Scientia Ventures
    PR Newswire

    New Ventures Funds Rebrands as Scientia Ventures

    New Ventures Funds has launched a new corporate brand identity and changed its name to Scientia Ventures. The new website for the firm can be found at: www.scientiavc.com. This reflects the broadening of the firm's strategic direction since launching its 3rd fund in 2017 to reflect its focus on transformational science and technology in healthcare. The announcement follows two recent successful IPO's of portfolio companies: ADC Therapeutics (NYSE: ADCT) and Royalty Pharma (NASDAQ: RPRX); and successful Phase 3 clinical trials for two of its portfolio companies: FibroGen (NASDAQ: FGEN) and Intra-Cellular Therapies (NASDAQ: ITCI).